Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event
02 February 2024 - 12:35AM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced that it
will present at the Virtual Investor New to the Street Event on
Wednesday, February 7, 2024 at 10:00 AM ET.
As part of the event, Lori Bisson, Chief
Executive Officer, Walter Klemp, Executive Chairman, Dr. Robert
Schwartz, Chief Medical Officer, and Trent Smith, Chief Financial
Officer of Autonomix Medical, will provide a corporate overview and
business outlook. In addition to the moderated discussion,
investors and interested parties will have the opportunity to
submit questions live during the event. The Company will answer as
many questions as possible in the time allowed.
A live video webcast of the event will be
available on the Events page under the Investors section of the
Company’s website (autonomix.com). A webcast replay will be
available two hours following the live event and will be accessible
for 90 days.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing our technology for
pancreatic cancer pain, a condition that can cause debilitating
pain and needs an effective solution. However, our technology
constitutes a platform with the potential to address dozens of
indications, including in cardiology, renal denervation and chronic
pain management across a wide disease spectrum.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Such forward-looking statements can be identified by
the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’
‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’
‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’
Although Autonomix Medical, Inc. (or Autonomix)
believes that the expectations reflected in these forward-looking
statements are based on reasonable assumptions, there are a number
of risks and uncertainties that could cause actual results to
differ materially from such forward-looking statements. You are
urged to carefully review and consider any cautionary statements
and other disclosures, including the statements made under the
heading “Risk Factors” and elsewhere in the offering statement
filed with the U.S. Securities and Exchange Commission (“SEC”).
Forward-looking statements speak only as of the date of the
document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media Contact
JTC Team, LLCJenene Thomas833-475-8247autonomix@jtcir.com
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
From Sep 2023 to Sep 2024